Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by bthoughtson Jun 05, 2015 1:25pm
224 Views
Post# 23801382

RE:RE:Nurogen Good - Profound(ly) Better

RE:RE:Nurogen Good - Profound(ly) Better

Hey MUGMODs,

You are not dreaming =)

Mr. Plymale says. “Our colleagues in the MR industry see this as the operating room of the future for applications beyond prostate cancer.”

The article where this is quoted from is a great summary of what Profound Inc is currently doing. If you are curious about them I highly recommend the quick read.

Another important key point mentioned by CEO, Steven Plymale "We expect to be cash flow positive by the end of 2017.”

Source:

https://biotuesdays.com/2015/05/26/profound-medical-seeking-ce-mark-for-tulsa-pro-this-year/

 

Bullboard Posts